Urol. praxi, 2011; 12(4): 238-245

Bone metastasis in prostate cancer and other urological malignancies - 2nd part

MUDr.Otakar Čapoun
Urologická klinika VFN a 1. LF UK v Praze

Treatment of advanced urological malignancies demands a multidisciplinary approach involving the urologist, clinical and radiation

oncologist, aftercare and rehabilitation and social care. Prostate cancer is the most common urological malignancy metastatic to the

bone. The primary treatment consists of androgen deprivation therapy together with skeletal-related events prevention, and secondary

hormonal manipulation or antiandrogen withdrawal in case of disease progression. For the next stage of disease some cytotoxic regimens

are warranted. Combined surgical and targeted systemic therapy is suitable in advanced renal cancer. Statistical models for treatmentresponse

prediction and survival prognosis were calculated for every single diagnosis. All patients with advanced urological malignancies

should be encouraged to take part in clinical trials.

Keywords: prostate cancer, bone metastasis, chemotherapy

Published: August 10, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čapoun O. Bone metastasis in prostate cancer and other urological malignancies - 2nd part. Urol. praxi. 2011;12(4):238-245.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010; 24(3): 39-51. Go to original source...
    2. Kolombo I, Kolombová J, Vlásek T. Místo bisfosfonátů při skeletovém postižení v uroonkologii. Urolog. Praxi 2006; 5: 228-242.
    3. Poršová M, Porš J, Kolombo I, et al. Současná léčba kostních metastáz. Urolog. Praxi 2007; 8: 272-280.
    4. Král M, Hrabec M, Grepl M, et al. Praktický přístup k pacientovi s kostními metastázami u urologických nádorů. Urolog. Praxi 2011; 12(1): 12-17.
    5. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223. Go to original source...
    6. Moul JW, Srivastava S, McLeod DG. Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol. 1995; 13(2): 157-163. Go to PubMed...
    7. Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112(11): 2393-2400. Go to original source... Go to PubMed...
    8. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial. J Clin Oncol. 2004; 22(6): 1025-1033. Go to original source... Go to PubMed...
    9. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate. 1984; 5(1): 93-100. Go to original source... Go to PubMed...
    10. Fizazi K, Le Maitre A, Hudes G, et al. Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8(11): 994-1000. Go to original source... Go to PubMed...
    11. Shamash J, Powles T, Sarker SJ, et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred iethylstilbestrol. Br J Cancer. 2011; 15; 104(4): 620-628. Go to original source... Go to PubMed...
    12. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 24; 375(9724): 1437-1446. Go to original source... Go to PubMed...
    13. Pal SK, Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas. 2011; 68(2): 103-105. Go to original source... Go to PubMed...
    14. A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednison in Patients With Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer. Clinical Study Protocol C21004.
    15. Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology. 2002; 60(4): 553-561. Go to original source... Go to PubMed...
    16. Foss? SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001; 19(1): 62-71. Go to original source... Go to PubMed...
    17. Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985; 3(6): 827-841. Go to original source... Go to PubMed...
    18. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71: 1098-1109. Go to original source...
    19. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17(8): 2506-2513. Go to original source... Go to PubMed...
    20. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502-1512. Go to original source... Go to PubMed...
    21. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242-245. Go to original source... Go to PubMed...
    22. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 7; 351(15): 1513-1520. Go to original source... Go to PubMed...
    23. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Cancer. 2008; 112(2): 326-330. Go to original source... Go to PubMed...
    24. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147-1154. Go to original source... Go to PubMed...
    25. Rosenberg JE, Kelly WK, Michaelson MD, et al. A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005; 23(16s): Abstract #4566. Go to original source...
    26. de Bono JS, Maroto P, Calvo E, et al. Phase II study of eribulin mesylate (E7389) in patients (patients) with metastatic castrationresistant prostate cancer (CRPC) stratified by prior taxane therapy. Proc Am Soc Clin Oncol. (2009 Genitourinary Cancer Symposium); Abstract #166.
    27. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822. Go to original source... Go to PubMed...
    28. Michaelson MD, Kaufman DS, Kantoff P, et al. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107: 530-535. Go to original source... Go to PubMed...
    29. Tombal B. Extending bone metastases-free survival in men with prostate cancer - future prospects. 26th Annual EAU Congress, Vienna. 18-22 March, 2011.
    30. Hoffman NE, Gillet MD, Cheville JC. Difference in organ system of distant metastses by mRCC subtypes. J Urol. 2008; 180: 474-477. Go to original source... Go to PubMed...
    31. Bhat S. Role of surgery in advanced/metastatic renal cell carcinoma. Indian J Urol. 2010; 26(2): 167-176. Go to original source... Go to PubMed...
    32. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cancer in the era of molecular targeted therapy. J Urol. 2007; 177: 1978-1984. Go to original source... Go to PubMed...
    33. Walther MM, Alexander RB, Wiess GH. Cytoreductive nephrectomy prior to IL2 based therapy in patients with metastatic renal cell cancer. Urology. 1993; 42: 250-254. Go to original source... Go to PubMed...
    34. Flanigan RC, Mickisch G, Sylvestor R. Cytoreductive nephrectomy in patients with metastatic renal cell cancer: A combined analysis. J Urol. 2004; 171: 1071-1076. Go to original source... Go to PubMed...
    35. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Eng J Med. 1998; 338: 1272-1278. Go to original source... Go to PubMed...
    36. Bullock A, McDermott DF, Atkins MB. Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res. 2010; 2: 123-132. Go to original source... Go to PubMed...
    37. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068. Go to original source... Go to PubMed...
    38. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55(4): 815-825. Go to original source... Go to PubMed...
    39. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22(2): 220-228. Go to original source... Go to PubMed...
    40. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7): 1232-1237. Go to original source... Go to PubMed...
    41. de Bono JS, Scher HI, Montgomery BR, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19): 6302-6309. Go to original source... Go to PubMed...
    42. Jung K, Lein M, Stephan C, Von HK, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-791. Go to original source... Go to PubMed...
    43. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-4935. Go to original source... Go to PubMed...
    44. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201. Go to original source... Go to PubMed...
    45. Motzer RJ, Mazumdar MJ, Bacik G, et al. Surgical and prognostic stratification of 670 patients with advanced renal cancer. J Clin Oncol. 1999; 17: 2530-2535. Go to original source... Go to PubMed...
    46. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer. 2009; 115(10 Suppl): 2273-81. Go to original source... Go to PubMed...
    47. Han KR, Pantuck AJ, Bui M. Number of metastatic site rather than the location of matastasis dictates overall survival of patients with N0 metastatic renal cancer. Urology. 2003; 69: 38407.
    48. Toyoda Y, Shinohara N, Harbayashi T, et al. Survival and prognostic classification of patients with metastatic renal cancer to bones. Eur Urol. 2007; 52: 163-169. Go to original source... Go to PubMed...
    49. Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010; 16(9): 693-702. Go to original source... Go to PubMed...
    50. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008; 14(5): 317-322.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.